Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
about
Use of Cell-Penetrating Peptides in Dendritic Cell-Based VaccinationNanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethyleniminesDelivery of therapeutic AGT shRNA by PEG-Bu for hypertension therapyA role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittindNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitisEnhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.Melittin derived peptides for nanoparticle based siRNA transfection.Importance of the difference in surface pressures of the cell membrane in doxorubicin resistant cells that do not express Pgp and ABCG2.Ternary nanoparticles composed of cationic solid lipid nanoparticles, protamine, and DNA for gene delivery.Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulationsCholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene.Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.Intracellular transduction and potential of Tat PTD and its analogs: from basic drug delivery mechanism to application.siRNA delivery: from lipids to cell-penetrating peptides and their mimics.Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with an Influenza Peptide and Transferrin Shell.Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.Inhibition of VEGF expression in A431 and MDA-MB-231 tumour cells by cationic lipid-mediated siRNA delivery.Chimeric peptide-mediated siRNA transduction to inhibit HIV-1 infection.Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery.Diseases originate and terminate by genes: unraveling nonviral gene delivery.Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity.Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza.
P2860
Q26764861-737DA819-FE45-4DCA-A242-4B5DF81563AAQ27692125-61C4C2C8-1A02-4A4B-A25D-AA943DBDF16BQ34231151-89E6177C-6CC3-47E5-BDCF-D4D5958A16CDQ34406423-7F7C32F1-1FE1-47F3-A501-A46F3090AE1BQ34872981-155897CB-D8A4-403E-B729-B66E07E89862Q35967737-7C99642D-1BCA-47FB-A170-1D7DFB0F5B96Q36085336-3FF2D57C-E2BC-49ED-8021-515A343745A2Q36354955-EC0AE623-6DC8-44EB-AA13-DD8314EFBF6AQ36626455-E02265BA-788D-482B-9B4C-0BFE626D2A3BQ37054441-C9EBE691-47CD-4E5A-B4D2-A17450364966Q37120644-B053FC7F-47F5-467D-87FC-E0C3280AEFA0Q37284677-681FBC57-76C4-4084-B894-4ADEFD3FF791Q37718210-6106F155-C140-4EC4-8C0D-4A8384B2600BQ37950261-E6C8E81F-7C70-4736-84D7-AB31F7F1DC06Q37995239-9C96231C-82AD-44F8-B9D4-C762363F9891Q38043064-115D7EE5-105B-4B91-A6CF-4BF56CAAF045Q38775787-1D317F76-3122-4A7E-9BB4-93791D1F44C3Q38777161-66D461DF-6B75-4765-ABEF-D105899AF433Q39369471-D1C620A4-0859-470A-A361-DC778AB623ECQ40472266-9D6A0CE0-0572-4992-8B02-D95A24832324Q41042177-0A7D4E43-3699-49AB-A492-0CD7BF9A4F45Q41197665-B4AEC3B7-0BE6-4169-96AB-5C254A31545EQ42226373-B65F7539-D70D-4699-BCD3-4B26109A6E52Q52958205-F8E9C1A8-A696-4851-924F-AA03C0B59D73Q55317717-FCDE9A39-E85B-4FFE-A48E-A41500D3218A
P2860
Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@en
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@nl
type
label
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@en
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@nl
prefLabel
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@en
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@nl
P50
P1476
Delivery of therapeutic shRNA ...... hronic Myeloid Leukemia cells.
@en
P2093
Yamini Arthanari
P304
P356
10.1016/J.JCONREL.2010.04.011
P407
P577
2010-04-24T00:00:00Z